We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for streaming realtime charts, analysis tools, and prices.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Recordati SpA | BIT:REC | Italy | Ordinary Share |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.40 | -0.79% | 50.35 | 50.05 | 50.70 | 51.20 | 50.15 | 50.90 | 129,287 | 02:00:55 |
From May 2019 to May 2024
LONDON--AstraZeneca PLC (AZN.LN) has entered into an agreement with Recordati S.p.A (REC.MI) for the commercial rights to AstraZeneca's heart-failure drug Seloken/Seloken ZOK and associated Logimax fixed-dose combination treatments in Europe.
AstraZeneca said Monday that Recordati will pay $300 million upon completion of the agreement. AstraZeneca will also receive sales-related income through tiered royalties, initially at a double-digit percentage of sales.
AstraZeneca said it will manufacture and supply the medicines to Recordati under a supply agreement.
-Write to Razak Musah Baba at razak.baba@wsj.com; Twitter: @Raztweet
(END) Dow Jones Newswires
May 22, 2017 02:31 ET (06:31 GMT)
Copyright (c) 2017 Dow Jones & Company, Inc.
1 Year Recordati Chart |
1 Month Recordati Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
